Related Experiment Video
Updated: Aug 18, 2026

The Collective Trust Game: An Online Group Adaptation of the Trust Game Based on the HoneyComb Paradigm
Published on: October 20, 2022
National cooperative group trials
Robert S Dipaola1, Ian M Thompson
1Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA. dipaolrs@umdnj.edu
Abstract:
Now is the time to answer critical questions in the management of prostate cancer through enrollment in high-priority national phase 3 clinical trials. Studies of systemic therapy before and after local therapy are vitally important to determine whether early systemic interventions might delay cancer progression. Chemotherapy must be studied in earlier disease progression. Novel targeted therapies, such as vaccine therapy, angiogenesis inhibitors, and newer microtubule targeting agents, should be studied in all stages of progression. Despite these needs and the availability of systemic therapies, accrual to trials has been lagging. This article reviews the national cooperative group clinical trials, whether currently open or planned, and suggests practical strategies to improve accrual.
Insights
High-priority prostate cancer clinical trials are crucial for advancing treatment. Improving patient enrollment in these systemic therapy studies is essential for better cancer management and outcomes.
Area of Science:
- Oncology
- Clinical Trials
- Prostate Cancer Management
Background:
- Critical questions remain in prostate cancer management, necessitating further research.
- Systemic therapies, including chemotherapy and novel targeted agents, require investigation across all disease stages.
- Accrual to national phase 3 clinical trials for prostate cancer has been insufficient.
Purpose of the Study:
- To review ongoing and planned national cooperative group clinical trials in prostate cancer.
- To identify and suggest practical strategies for improving clinical trial enrollment.
- To emphasize the importance of systemic therapy research in prostate cancer management.
Main Methods:
- Review of national cooperative group clinical trials for prostate cancer.
- Analysis of current and planned trial designs focusing on systemic therapies.
- Identification of barriers and facilitators to clinical trial accrual.
Main Results:
- Several high-priority phase 3 clinical trials are open or planned for prostate cancer.
- Systemic therapy research is vital for earlier disease stages and novel targeted agents.
- Lagging accrual rates pose a significant challenge to advancing prostate cancer research.
Conclusions:
- Enrollment in national phase 3 clinical trials is critical for answering key questions in prostate cancer management.
- Improved accrual strategies are needed to facilitate the timely completion of vital research.
- Further investigation of chemotherapy and novel targeted therapies is essential for all stages of prostate cancer progression.
Related Concept Videos
Robbers Cave
Clinical Trials: Overview
Trial and Error and Algorithm
Cochran's Q Test
Experimental Designs
Testing a Claim about Population Proportion
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...

